CN116715633B - 可用于降尿酸的化合物 - Google Patents

可用于降尿酸的化合物

Info

Publication number
CN116715633B
CN116715633B CN202310469300.3A CN202310469300A CN116715633B CN 116715633 B CN116715633 B CN 116715633B CN 202310469300 A CN202310469300 A CN 202310469300A CN 116715633 B CN116715633 B CN 116715633B
Authority
CN
China
Prior art keywords
group
alkyl
substituted
compound
carbonyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310469300.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN116715633A (zh
Inventor
史东方
傅长金
杨艳
李海明
袁承诣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou New Element Pharmaceutical Co ltd
Atom Therapeutics Co Ltd
Original Assignee
Hangzhou New Element Pharmaceutical Co ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou New Element Pharmaceutical Co ltd, Jiangsu Atom Bioscience and Pharmaceutical Co Ltd filed Critical Hangzhou New Element Pharmaceutical Co ltd
Publication of CN116715633A publication Critical patent/CN116715633A/zh
Application granted granted Critical
Publication of CN116715633B publication Critical patent/CN116715633B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310469300.3A 2022-04-27 2023-04-27 可用于降尿酸的化合物 Active CN116715633B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022104569393 2022-04-27
CN202210456939 2022-04-27

Publications (2)

Publication Number Publication Date
CN116715633A CN116715633A (zh) 2023-09-08
CN116715633B true CN116715633B (zh) 2025-08-12

Family

ID=87872273

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310469300.3A Active CN116715633B (zh) 2022-04-27 2023-04-27 可用于降尿酸的化合物

Country Status (6)

Country Link
US (1) US20250282753A1 (https=)
EP (1) EP4516781A4 (https=)
JP (1) JP7792730B2 (https=)
CN (1) CN116715633B (https=)
TW (1) TWI870839B (https=)
WO (1) WO2023208108A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160299A (zh) * 2021-04-29 2022-10-11 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336142T3 (es) * 2005-08-19 2010-04-08 Aventis Pharmaceuticals Inc. Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo.
JP5222561B2 (ja) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2010044403A1 (ja) 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
CA2739058A1 (en) * 2008-10-15 2010-04-22 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and use thereof for medical purposes
KR20100092909A (ko) * 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
DK2669270T3 (en) * 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN105189476B (zh) 2013-03-29 2017-07-07 帝人制药株式会社 吡唑衍生物
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
KR20170105021A (ko) 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
JP6873904B2 (ja) 2015-08-28 2021-05-19 Ils株式会社 キサンチンオキシダーゼ阻害剤
RU2733750C2 (ru) * 2015-09-02 2020-10-06 Саншайн Лейк Фарма Ко., Лтд. Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
KR102109061B1 (ko) * 2015-09-10 2020-05-11 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 고요산혈증 또는 통풍을 치료 또는 예방하는 화합물
CN107759588B (zh) * 2016-08-19 2020-10-23 江苏新元素医药科技有限公司 一类苯基-(吡唑并[1,5-a]吡啶-3-基)甲酮衍生物
MX2021000887A (es) * 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN116438175B (zh) * 2020-11-11 2025-07-22 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160299A (zh) * 2021-04-29 2022-10-11 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Also Published As

Publication number Publication date
JP7792730B2 (ja) 2025-12-26
EP4516781A1 (en) 2025-03-05
CN116715633A (zh) 2023-09-08
TWI870839B (zh) 2025-01-21
JP2025514336A (ja) 2025-05-02
WO2023208108A1 (zh) 2023-11-02
TW202342456A (zh) 2023-11-01
EP4516781A4 (en) 2026-04-29
US20250282753A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
ES2647437T3 (es) Compuestos y procedimientos para tratar el VIH
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
ES2616042T3 (es) Pirazolopiridinas sustituidas con bencilo y su uso
BR112012030010A2 (pt) 5-flúor-1h-pirazolopiridinas substituídas e seu uso
ES3059451T3 (en) Compound used as ret kinase inhibitor and application thereof
CN116715633B (zh) 可用于降尿酸的化合物
US9034894B2 (en) Derivate, preparation method and use of 10-methoxycamptothecin
CN115974855B (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
JP2022549496A (ja) Ｃｒｆ受容体アンタゴニストおよび使用方法
JP2025514336A5 (https=)
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
CN116836154B (zh) 可用于痛风的化合物
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
TWI922802B (zh) 可用於痛風的化合物
CN113354616B (zh) 二芳基-1,2,4-三唑类化合物及其制法和药物用途
HK40128990A (en) Carbonyl fused heterocyclic derivative used as ubiquitin-specific protease inhibitor
JP2025531133A (ja) ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体
CN121378170A (zh) 用于抑制bcr-abl1活性的苯并噻唑类衍生物
HK40078398A (en) Class of xanthine oxidase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: China

Address after: Room 306, Building 21, Hexiang Technology Center, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province 311222

Applicant after: Hangzhou New Element Pharmaceutical Co.,Ltd.

Address before: Unit 401, C31, Biomedical Industrial Park, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Wujiang District, Suzhou City, Jiangsu Province

Applicant before: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 310018 Zhejiang Province, Hangzhou City, Qiantang District, Xiaoshan Street, Yinhai Science and Technology Innovation Center, Building 10, Room 201-1

Applicant after: Hangzhou New Element Pharmaceutical Co.,Ltd.

Address before: Room 306, Building 21, Hexiang Technology Center, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province

Applicant before: Hangzhou New Element Pharmaceutical Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant